BACKGROUND AND OBJECTIVES: In view of the increasing prevalence of morbidly obese patients, the influence of excessive total bodyweight (TBW) on the pharmacokinetics and pharmacodynamics of propofol was characterized in this study using bispectral index (BIS) values as a pharmacodynamic endpoint. METHODS: A population pharmacokinetic and pharmacodynamic model was developed with the nonlinear mixed-effects modelling software NONMEM VI, on the basis of 491 blood samples from 20 morbidly obese patients (TBW range 98-167 kg) and 725 blood samples from 44 lean patients (TBW range 55-98 kg) from previously published studies. In addition, 2246 BIS values from the 20 morbidly obese patients were available for pharmacodynamic analysis. RESULTS: In a three-compartment pharmacokinetic model, TBW proved to be the most predictive covariate for clearance from the central compartment (CL) in the 20 morbidly obese patients (CL 2.33 L/min × [TBW/70]^[0.72]). Similar results were obtained when the morbidly obese patients and the 44 lean patients were analysed together (CL 2.22 L/min × [TBW/70]^[0.67]). No covariates were identified for other pharmacokinetic parameters. The depth of anaesthesia in the morbidly obese patients was adequately described by a two-compartment biophase-distribution model with a sigmoid maximum possible effect (E(max)) pharmacodynamic model (concentration at half-maximum effect [EC(50)] 2.12 mg/L) without covariates. CONCLUSION: We developed a pharmacokinetic and pharmacodynamic model of propofol in morbidly obese patients, in which TBW proved to be the major determinant of clearance, using an allometric function with an exponent of 0.72. For the other pharmacokinetic and pharmacodynamic parameters, no covariates could be identified. Trial registration number (clinicaltrials.gov): NCT00395681.
BACKGROUND AND OBJECTIVES: In view of the increasing prevalence of morbidly obesepatients, the influence of excessive total bodyweight (TBW) on the pharmacokinetics and pharmacodynamics of propofol was characterized in this study using bispectral index (BIS) values as a pharmacodynamic endpoint. METHODS: A population pharmacokinetic and pharmacodynamic model was developed with the nonlinear mixed-effects modelling software NONMEM VI, on the basis of 491 blood samples from 20 morbidly obesepatients (TBW range 98-167 kg) and 725 blood samples from 44 lean patients (TBW range 55-98 kg) from previously published studies. In addition, 2246 BIS values from the 20 morbidly obesepatients were available for pharmacodynamic analysis. RESULTS: In a three-compartment pharmacokinetic model, TBW proved to be the most predictive covariate for clearance from the central compartment (CL) in the 20 morbidly obesepatients (CL 2.33 L/min × [TBW/70]^[0.72]). Similar results were obtained when the morbidly obesepatients and the 44 lean patients were analysed together (CL 2.22 L/min × [TBW/70]^[0.67]). No covariates were identified for other pharmacokinetic parameters. The depth of anaesthesia in the morbidly obesepatients was adequately described by a two-compartment biophase-distribution model with a sigmoid maximum possible effect (E(max)) pharmacodynamic model (concentration at half-maximum effect [EC(50)] 2.12 mg/L) without covariates. CONCLUSION: We developed a pharmacokinetic and pharmacodynamic model of propofol in morbidly obesepatients, in which TBW proved to be the major determinant of clearance, using an allometric function with an exponent of 0.72. For the other pharmacokinetic and pharmacodynamic parameters, no covariates could be identified. Trial registration number (clinicaltrials.gov): NCT00395681.
Authors: Catherijne A J Knibbe; Klaas P Zuideveld; Joost DeJongh; Paul F M Kuks; Leon P H J Aarts; Meindert Danhof Journal: Clin Pharmacol Ther Date: 2002-12 Impact factor: 6.875
Authors: Luca La Colla; Andrea Albertin; Giorgio La Colla; Valerio Ceriani; Tiziana Lodi; Andrea Porta; Giorgio Aldegheri; Alberto Mangano; Ilias Khairallah; Isabella Fermo Journal: Eur J Anaesthesiol Date: 2009-05 Impact factor: 4.330
Authors: Cynthia L Ogden; Margaret D Carroll; Lester R Curtin; Margaret A McDowell; Carolyn J Tabak; Katherine M Flegal Journal: JAMA Date: 2006-04-05 Impact factor: 56.272
Authors: Simone van Kralingen; Jeroen Diepstraten; Ewoudt M W van de Garde; Ary-Jan van der Lely; Eric P A van Dongen; Bert van Ramshorst; Catherijne A J Knibbe Journal: Eur J Anaesthesiol Date: 2010-06 Impact factor: 4.330
Authors: D A Ferreira; C S Nunes; L M Antunes; I A Santos; F Lobo; M Casal; L Ferreira; P Amorim Journal: Eur J Anaesthesiol Date: 2006-02-10 Impact factor: 4.330
Authors: Célia Lloret Linares; Xavier Declèves; Jean Michel Oppert; Arnaud Basdevant; Karine Clement; Christophe Bardin; Jean Michel Scherrmann; Jean Pierre Lepine; Jean François Bergmann; Stéphane Mouly Journal: Clin Pharmacokinet Date: 2009 Impact factor: 6.447
Authors: Douglas J Eleveld; Johannes H Proost; Anthony R Absalom; Michel M R F Struys Journal: Clin Pharmacokinet Date: 2011-11-01 Impact factor: 6.447
Authors: Margreke J E Brill; Jeroen Diepstraten; Anne van Rongen; Simone van Kralingen; John N van den Anker; Catherijne A J Knibbe Journal: Clin Pharmacokinet Date: 2012-05-01 Impact factor: 6.447
Authors: Jeroen Diepstraten; Vidya Chidambaran; Senthilkumar Sadhasivam; Hope R Esslinger; Shareen L Cox; Thomas H Inge; Catherijne A J Knibbe; Alexander A Vinks Journal: Clin Pharmacokinet Date: 2012-08 Impact factor: 6.447
Authors: Kathryn E Kyler; Jonathan Wagner; Chelsea Hosey-Cojocari; Kevin Watt; Valentina Shakhnovich Journal: Paediatr Drugs Date: 2019-10 Impact factor: 3.022